Monte Rosa Therapeutics I... (GLUE)
Monte Rosa Therapeutics Statistics
Share Statistics
Monte Rosa Therapeutics has 61.51M shares outstanding. The number of shares has increased by 0.59% in one year.
| Shares Outstanding | 61.51M |
| Shares Change (YoY) | 0.59% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 74.36% |
| Shares Floating | 45.99M |
| Failed to Deliver (FTD) Shares | 68 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 8.76M, so 14.25% of the outstanding shares have been sold short.
| Short Interest | 8.76M |
| Short % of Shares Out | 14.25% |
| Short % of Float | 19.06% |
| Short Ratio (days to cover) | 6.9 |
Valuation Ratios
The PE ratio is -7.06 and the forward PE ratio is -3.65. Monte Rosa Therapeutics's PEG ratio is 0.11.
| PE Ratio | -7.06 |
| Forward PE | -3.65 |
| PS Ratio | 6.78 |
| Forward PS | 2.1 |
| PB Ratio | 2.3 |
| P/FCF Ratio | 13.5 |
| PEG Ratio | 0.11 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Monte Rosa Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.4 |
| Quick Ratio | 2.4 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.53 |
| Debt / FCF | 1.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $564.34K |
| Profits Per Employee | $-542.54K |
| Employee Count | 134 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.57M |
| Effective Tax Rate | -3.66% |
Stock Price Statistics
The stock price has increased by -35% in the last 52 weeks. The beta is 1.5, so Monte Rosa Therapeutics's price volatility has been higher than the market average.
| Beta | 1.5 |
| 52-Week Price Change | -35% |
| 50-Day Moving Average | 6.08 |
| 200-Day Moving Average | 6.08 |
| Relative Strength Index (RSI) | 29.43 |
| Average Volume (20 Days) | 735.58K |
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 75.62M and earned -72.7M in profits. Earnings per share was -0.98.
| Revenue | 75.62M |
| Gross Profit | 75.62M |
| Operating Income | -81.11M |
| Net Income | -72.7M |
| EBITDA | -81.11M |
| EBIT | -81.11M |
| Earnings Per Share (EPS) | -0.98 |
Balance Sheet
The company has 224.25M in cash and 42.72M in debt, giving a net cash position of 181.54M.
| Cash & Cash Equivalents | 224.25M |
| Total Debt | 42.72M |
| Net Cash | 181.54M |
| Retained Earnings | -438.59M |
| Total Assets | 438.73M |
| Working Capital | 220.49M |
Cash Flow
In the last 12 months, operating cash flow was 42M and capital expenditures -3.99M, giving a free cash flow of 38.01M.
| Operating Cash Flow | 42M |
| Capital Expenditures | -3.99M |
| Free Cash Flow | 38.01M |
| FCF Per Share | 0.51 |
Margins
Gross margin is 100%, with operating and profit margins of -107.26% and -96.14%.
| Gross Margin | 100% |
| Operating Margin | -107.26% |
| Pretax Margin | -92.74% |
| Profit Margin | -96.14% |
| EBITDA Margin | -107.26% |
| EBIT Margin | -107.26% |
| FCF Margin | 50.26% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GLUE is $16, which is 262% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 262% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -0.44 |
| Piotroski F-Score | 4 |